# Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer

## TL;DR

This study examines which patients with BRCA1/2 mutations are eligible for olaparib treatment after breast cancer and compares their characteristics and outcomes.

## Contribution

The study provides real-world data on eligibility for adjuvant olaparib in BRCA1/2 mutation carriers with early breast cancer.

## Key findings

- Identified the proportion of BRCA1/2 mutation carriers eligible for olaparib based on OlympiA criteria.
- Compared clinicopathologic features and outcomes between eligible and ineligible patients.

## Abstract

Following the survival benefit demonstrated in the OlympiA trial, one year of adjuvant olaparib is now recommended for all patients with germline BRCA1/2 pathogenic/likely pathogenic variants (PV) and high-risk, HER2-negative early breast cancer after chemotherapy. However, optimal identification of high-risk patients who may derive benefit from this genomically-directed therapy is debated. In this study, we sought to characterize the real-world proportion of gBRCA1/2 PV carriers eligible for adjuvant olaparib according to the OlympiA criteria, and to compare clinicopathologic characteristics and outcomes between eligible and ineligible patients.